Hepatitis

Hepatitis
Classification and external resources

Alcoholic hepatitis evident by fatty change, cell necrosis, Mallory bodies
ICD-10 K75.9
ICD-9 573.3
DiseasesDB 20061
MeSH D006505

Hepatitis (plural hepatitides) is a medical condition defined by the inflammation of the liver and characterized by the presence of inflammatory cells in the tissue of the organ. The name is from the Greek hepar (ἧπαρ), the root being hepat- (ἡπατ-), meaning liver, and suffix -itis, meaning "inflammation" (c. 1727).[1] The condition can be self-limiting (healing on its own) or can progress to fibrosis (scarring) and cirrhosis.

Hepatitis may occur with limited or no symptoms, but often leads to jaundice, anorexia (poor appetite) and malaise. Hepatitis is acute when it lasts less than six months and chronic when it persists longer. A group of viruses known as the hepatitis viruses cause most cases of hepatitis worldwide, but it can also be due to toxins (notably alcohol, certain medications, some industrial organic solvents and plants), other infections and autoimmune diseases.

Contents

Signs and symptoms

Acute

Initial features are of nonspecific flu-like symptoms, common to almost all acute viral infections and may include malaise, muscle and joint aches, fever, nausea or vomiting, diarrhea, and headache. More specific symptoms, which can be present in acute hepatitis from any cause, are: profound loss of appetite, aversion to smoking among smokers, dark urine, yellowing of the eyes and skin (i.e., jaundice) and abdominal discomfort. Physical findings are usually minimal, apart from jaundice in a third and tender hepatomegaly (swelling of the liver) in about 10%. Some exhibit lymphadenopathy (enlarged lymph nodes, in 5%) or splenomegaly (enlargement of the spleen, in 5%).[2]

Acute viral hepatitis is more likely to be asymptomatic in younger people. Symptomatic individuals may present after convalescent stage of 7 to 10 days, with the total illness lasting 2 to 6 weeks.[3]

A small proportion of people with acute hepatitis progress to acute liver failure, in which the liver is unable to clear harmful substances from the circulation (leading to confusion and coma due to hepatic encephalopathy) and produce blood proteins (leading to peripheral edema and bleeding). This may become life-threatening and occasionally requires a liver transplant.

Chronic

Chronic hepatitis often leads to nonspecific symptoms such as malaise, tiredness and weakness, and often leads to no symptoms at all. It is commonly identified on blood tests performed either for screening or to evaluate nonspecific symptoms. The occurrence of jaundice indicates advanced liver damage. On physical examination there may be enlargement of the liver.[4]

Extensive damage and scarring of liver (i.e. cirrhosis) leads to weight loss, easy bruising and bleeding tendencies, peripheral edema (swelling of the legs) and accumulation of ascites (fluid in the abdominal cavity). Eventually, cirrhosis may lead to various complications: esophageal varices (enlarged veins in the wall of the esophagus that can cause life-threatening bleeding) hepatic encephalopathy (confusion and coma) and hepatorenal syndrome (kidney dysfunction).

Acne, abnormal menstruation, lung scarring, inflammation of the thyroid gland and kidneys may be present in women with autoimmune hepatitis.[4]

Pathology

The liver, like all organs, responds to injury in a limited number of ways and a number of pattens have been identified. Liver biopsies are rarely performed for acute hepatitis and because of this the histology of chronic hepatitis is better known than that of acute hepatitis.

Acute

In acute hepatitis the lesions (areas of abnormal tissue) predominantly contain diffuse sinusoidal and portal mononuclear infiltrates (lymphocytes, plasma cells, Kupffer cells) and swollen hepatocytes. Acidophilic cells (Councilman bodies) are common. Hepatocyte regeneration and cholestasis (canalicular bile plugs) typically are present. Bridging hepatic necrosis (areas of necrosis connecting two or more portal tracts) may also occur. There may be some lobular disarray. Although aggregates of lymphocytes in portal zones may occur these are usually neither common nor prominent. The normal architecture is preserved. There is no evidence of fibrosis or cirrhosis (fibrosis plus regenerative nodules). In severe cases prominent hepatocellular necrosis around the central vein (zone 3) may be seen.

In submassive necrosis – a rare presentation of acute hepatitis – there is widespread hepatocellular necrosis beginning in the centrizonal distribution and progressing towards portal tracts. The degree of parenchymal inflammation is variable and is proportional to duration of disease.[5][6] Two distinct patterns of necrosis have been recognised: (1) zonal coagulative necrosis or (2) panlobular (nonzonal) necrosis.[7] Numerous macrophages and lymphocytes are present. Necrosis and inflammation of the biliary tree occurs.[8] Hyperplasia of the surviving biliary tract cells may be present. Stromal haemorrhage is common.

The histology may show some correlation with the cause:

Where patients have recovered from this condition, biopsies commonly show multiacinar regenerative nodules (previously known as adenomatous hyperplasia).[9]

Massive hepatic necrosis is also known and is usually rapidly fatal. The pathology resembles that of submassive necrosis but is more markered in both degree and extent.

Chronic

Chronic hepatitis has been better studied and several conditions have been described.

Chronic active hepatitis was the term used to described cases of hepatitis for more than 6 months with portal based inflammation, fibrosis, disruption of the terminal plate and piecemeal necrosis. This term has now been replaced by the diagnosis of 'chronic hepatitis with piecemeal (periportal) necrosis (or interface hepatitis) with or without fibrosis.'[10]

Chronic persistent hepatitis was the term used to describe chronic hepatitis with no significant periportal necrosis or regeneration with a fairly dense mononuclear portal infiltrate. Councilman bodies are frequently seen within the lobule. This condition is now referred to as 'chronic hepatitis without piecemeal necrosis (or interface hepatitis).'[10]

Chronic lobular hepatitis was the term used to describe chronic hepatitis with persistent parenchymal focal hepatocyte necrosis (apoptosis) with mononuclear sinusoidal infiltrates. This is now referred to as 'chronic hepatitis without piecemeal necrosis (or interface hepatitis).'[10]

These terms have since been deprecated.[10] This was done because it was realised that these conditions could alter over time and what might have been regarded as a relatively benign lesion could still progress to cirrhosis. The simpler term 'chronic hepatitis' is now preferred in association with the causative agent (when known) and a grade based on the degree of inflammation, piecemeal or bridging necrosis (interface hepatitis) and the stage of fibrosis. Several grading systems have been proposed but none have been adopted universally.

Cirrhosis is a diffuse process characterized by regenerative nodules that are separated from one another by bands of fibrosis. It is the end stage for many chronic liver diseases. The pathophysiological process that results in cirrhosis is as follows: hepatocytes are lost through a gradual process of hepatocellular injury and inflammation. This injury stimulates a regenerative response in the remaining hepatocytes. The fibrotic scars limit the extent to which the normal architecture can be reestablished as the scars isolate groups of hepatocytes. This results in nodules formation. Angiogenisis (new vessel formation) accompanies scar production which results in the formation of abnormal channels between the central hepatic veins and the portal vessels. This in turn causes shunting of blood around the regenerating parenchyma. Normal vascular structures including the sinusoidal channels may be obliterated by fibrotic tissue leading to portal hypertension. The overall reduction in hepatocyte mass, in conjunction with the portal blood shunting, prevents the liver from accomplishing its usual functions – the filtering of blood from the gastrointestinal tract and serum protein production. These changes give rise to the clinical manifestations of cirrhosis.

Specific cases

Most of the causes of hepatitis cannot be distinguished on the basis of the pathology but some do have particular features that are suggestive of a particular diagnosis.

The presence of micronodular cirrhosis, Mallory bodies and fatty change within a single biopsy are highly suggestive of alcoholic injury.[11] Perivenular, pericellular fibrosis (known as 'chicken wire fibrosis' because of its appearance on trichrome or van Gieson stains) with partial or complete obliteration of the central vein is also very suggestive of alcohol abuse.

Cardiac, ischemic and venous outflow obstruction all cause similar patterns.[12] The sinusoids are often dilated and filled with erythrocytes. The liver cell plates may be compressed. Coagulative necrosis of the hepatocytes can occur around the central vein. Hemosiderin and lipochrome laden macrophages and inflammatory cells may be found. At the edge of the fibrotic zone cholestasis may be present. The portal tracts are rarely significantly involved until late in the course.

Biliary tract disease including primary biliary cirrhosis, sclerosing cholangitis, inflammatory changes associated with idiopathic inflammatory bowel disease and duct obstruction have similar histology in their early stages. Although these diseases tend to primarily involve the biliary tract they may also be associated with chronic inflammation within the liver and difficult to distinguish on histological grounds alone. The fibrotic changes associated with these disease principally involve the portal tracts with cholangiole proliferation, portal tract inflammation with neutrophils surrounding the cholangioles, disruption of the terminal plate by mononuclear inflammatory cells and occasional hepatocyte necrosis. The central veins are either not involved in the fibrotic process or become involved only late in the course of the disease. Consequently the central–portal relationships are minimally distorted. Where cirrhosis is present it tends to be in the form of a portal–portal bridging fibrosis.

Hepatitis E causes different histological patterns that depend on the host's background.[13] In immunocompetent patients the typical pattern is of severe intralobular necrosis and acute cholangitis in the portal tract with numerous neutrophils. This normally resolves without sequelae. Disease is more severe in those with preexisting liver disease such as cirrhosis. In the immunocompromised patients chronic infection may result with rapid progression to cirrhosis. The histology is similar to that found in hepatitis C virus with dense lymphocytic portal infiltrate, constant peacemeal necrosis and fibrosis.

Causes

Acute

Chronic

Discussion

Alcoholic hepatitis

Main article: Alcoholic hepatitis

Ethanol, mostly in alcoholic beverages, is a significant cause of hepatitis. Usually alcoholic hepatitis comes after a period of increased alcohol consumption. Alcoholic hepatitis is characterized by a variable constellation of symptoms, which may include feeling unwell, enlargement of the liver, development of fluid in the abdomen ascites, and modest elevation of liver blood tests. Alcoholic hepatitis can vary from mild with only liver test elevation to severe liver inflammation with development of jaundice, prolonged prothrombin time, and liver failure. Severe cases are characterized by either obtundation (dulled consciousness) or the combination of elevated bilirubin levels and prolonged prothrombin time; the mortality rate in both categories is 50% within 30 days of onset.

Alcoholic hepatitis is distinct from cirrhosis caused by long term alcohol consumption. Alcoholic hepatitis can occur in patients with chronic alcoholic liver disease and alcoholic cirrhosis. Alcoholic hepatitis by itself does not lead to cirrhosis, but cirrhosis is more common in patients with long term alcohol consumption. Patients who drink alcohol to excess are also more often than others found to have hepatitis C. The combination of hepatitis C and alcohol consumption accelerates the development of cirrhosis.

Drug-induced

Main article: Hepatotoxicity

A large number of drugs can cause hepatitis:[78]

The clinical course of drug-induced hepatitis is quite variable, depending on the drug and the patient's tendency to react to the drug. For example, halothane hepatitis can range from mild to fatal as can INH-induced hepatitis. Hormonal contraception can cause structural changes in the liver. Amiodarone hepatitis can be untreatable since the long half life of the drug (up to 60 days) means that there is no effective way to stop exposure to the drug. Statins can cause elevations of liver function blood tests normally without indicating an underlying hepatitis. Lastly, human variability is such that any drug can be a cause of hepatitis.

Other toxins

Other Toxins can cause hepatitis:

Metabolic disorders

Some metabolic disorders cause different forms of hepatitis. Hemochromatosis (due to iron accumulation) and Wilson's disease (copper accumulation) can cause liver inflammation and necrosis.

Non-alcoholic steatohepatitis (NASH) is effectively a consequence of metabolic syndrome.

Obstructive

"Obstructive jaundice" is the term used to describe jaundice due to obstruction of the bile duct (by gallstones or external obstruction by cancer). If longstanding, it leads to destruction and inflammation of liver tissue.

Autoimmune

Anomalous presentation of human leukocyte antigen (HLA) class II on the surface of hepatocytes, possibly due to genetic predisposition or acute liver infection; causes a cell-mediated immune response against the body's own liver, resulting in autoimmune hepatitis.

Alpha 1-antitrypsin deficiency

In severe cases of alpha 1-antitrypsin deficiency (A1AD), the accumulated protein in the endoplasmic reticulum causes liver cell damage and inflammation.

Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is the occurrence of fatty liver in people who have no history of alcohol use. It is most commonly associated with obesity (80% of all obese people have fatty liver). It is more common in women. Severe NAFLD leads to inflammation, a state referred to as non-alcoholic steatohepatitis (NASH), which on biopsy of the liver resembles alcoholic hepatitis (with fat droplets and inflammatory cells, but usually no Mallory bodies).

The diagnosis depends on medical history, physical exam, blood tests, radiological imaging and sometimes a liver biopsy. The initial evaluation to identify the presence of fatty infiltration of the liver is medical imaging, including such ultrasound, computed tomography (CT), or magnetic resonance (MRI). However, imaging cannot readily identify inflammation in the liver. Therefore, the differentiation between steatosis and NASH often requires a liver biopsy. It can also be difficult to distinguish NASH from alcoholic hepatitis when the patient has a history of alcohol consumption. Sometimes in such cases a trial of abstinence from alcohol along with follow-up blood tests and a repeated liver biopsy are required.

NASH is becoming recognized as the most important cause of liver disease second only to hepatitis C in numbers of patients going on to cirrhosis.

Ischemic hepatitis

Main article: Ischemic hepatitis

Ischemic hepatitis is caused by decreased circulation to the liver cells. Usually this is due to decreased blood pressure (or shock), leading to the equivalent term "shock liver". Patients with ischemic hepatitis are usually very ill due to the underlying cause of shock. Rarely, ischemic hepatitis can be caused by local problems with the blood vessels that supply oxygen to the liver (such as thrombosis, or clotting of the hepatic artery which partially supplies blood to liver cells). Blood testing of a person with ischemic hepatitis will show very high levels of transaminase enzymes (AST and ALT), which may exceed 1000 U/L. The elevation in these blood tests is usually transient (lasting 7 to 10 days). It is rare that liver function will be affected by ischemic hepatitis.

Giant cell hepatitis

Giant cell hepatitis is a rare form of hepatitis (~100 cases reported) that predominantly occurs in children. Diagnosis is made on the basis of the presence of hepatocellular multinucleate giant cells.[82][83][7] Cases presenting in adults are rare and tend to be rapidly progressive.[84][85][86][87][88] The cause is currently unknown but an infectious cause is suspected.[89][90]The condition tends to improve with the use of ribivirin suggesting a viral origin.[91][92] Hepatitis E[93], hepatitis C,[94] paramyxovirus[95][96][97][98], papillomavirus[99][100] and Human herpes virus 6[101][102] have been suggested as causes. A similar condition has been reported in cats but it is not known if there is any connection between these conditions.[103]

See also

References

  1. ^ Online Etymology Dictionary
  2. ^ Ryder S, Beckingham I (2001). "Acute hepatitis". BMJ 322 (7279): 151–153. doi:10.1136/bmj.322.7279.151. PMC 1119417. PMID 11159575. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1119417. 
  3. ^ a b V.G. Bain and M. Ma, Acute Viral Hepatitis, Chapter 14, First principle of gastroenterology (an online text book)
  4. ^ a b Chronic hepatitis at Merck Manual of Diagnosis and Therapy Home Edition
  5. ^ Boyer JL, Klatskin G (1970). "Pattern of necrosis in acute viral hepatitis. Prognostic value of bridging (subacute hepatic necrosis)". N. Engl. J. Med. 283 (20): 1063–71. doi:10.1056/NEJM197011122832001. PMID 4319402. 
  6. ^ Gimson AE (1996) Fulminant and late onset hepatic failure. Br J Anaesthesia 77 (1): 90–98 PMID 8703634
  7. ^ a b Kirsch R, Yap J, Roberts EA, Cutz E (2009) Clinicopathologic spectrum of massive and submassive hepatic necrosis in infants and children. Hum Pathol 40(4):516–526
  8. ^ Nakanuma Y, Sasaki M, Terada T, Harada K (1994) Intrahepatic peribiliary glands of humans. II. Pathological spectrum. J Gastroenterol Hepatol 9(1):80–86
  9. ^ Wanless I, Callea F, Craig J, Crawford J, Desmet VJ, Farber E, et al. (1995) Terminology of nodular lesions of the liver. Hepatology 25: 983–993
  10. ^ a b c d Gastroenterology IWPotWCo (1994) Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an International Working Party, supported by the World Congresses of Gastroenterology, Los Angeles. Am J Gastroenterol 89: S177–81
  11. ^ Baptista A, Bianchi L, De Groote J, Desmet V, Gedigk P, Korb G, et al. (1981) Alcoholic liver disease: morphological manifestations. Lancet 1: 707–711
  12. ^ Arcidi J, Moore G, Hutchins G (1981) Hepatic morphology in cardiac dysfunction: a clinico-pathologic study of 1000 subjects at autopsy. Am J Pathol 104: 159–66
  13. ^ Selves J, Kamar N, Mansuy JM, Péron JM (2010) Hepatitis E virus: A new entity. Ann Pathol 30(6):432-438
  14. ^ a b c d e Miguet JP, Coaquette A, BressonHadni S, Lab M (1990) The other types of viral hepatitis. Rev Prat 40(18):16561659
  15. ^ Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, Palacios G, Khristova ML, Weyer J, Swanepoel R, Egholm M, Nichol ST, Lipkin WI (2009) Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 5(5):e1000455.
  16. ^ Appannanavar SB, Mishra B (2011) An update on crimean congo hemorrhagic fever. J Glob Infect Dis 3(3):285–292
  17. ^ Peters W (2002) Novel and challenging infections of man. A brief overview. Parassitologia 44(1–2):33–42
  18. ^ Glass GE, Watson AJ, LeDuc JW, Childs JE (1994) Domestic cases of hemorrhagic fever with renal syndrome in the United States. Nephron 68(1):48–51
  19. ^ Olsson GE, Leirs H, Henttonen H (2010) Hantaviruses and their hosts in Europe: reservoirs here and there, but not everywhere? Vector Borne Zoonotic Dis 10(6):549–561
  20. ^ Ikegami T, Makino S (2011) The pathogenesis of Rift Valley fever. Viruses 3(5):493–519
  21. ^ Burke RL, Kronmann KC, Daniels CC, Meyers M, Byarugaba DK, Dueger E, Klein TA, Evans BP, Vest KG (2011) A review of zoonotic disease surveillance supported by the Armed Forces Health Surveillance Center. Zoonoses Public Health. doi: 10.1111/j.1863 2378.2011.01440.x.
  22. ^ Weiss SR, Leibowitz JL (2011) Coronavirus pathogenesis. Adv Virus Res 81:85–164
  23. ^ a b Naides SJ (May 1998). "Rheumatic manifestations of parvovirus B19 infection". Rheum. Dis. Clin. North Am. 24 (2): 375–401. doi:10.1016/S0889857X(05)700144. PMID 9606764. 
  24. ^ Charrel RN, de Lamballerie X (2003) The Alkhurma virus (family Flaviviridae, genus Flavivirus): an emerging pathogen responsible for hemorrhage fever in the Middle East. Med Trop (Mars) 63(3):296–299
  25. ^ Ramos-De La Medina A, Remes-Troche JM, González-Medina MF, Anitúa-Valdovinos Mdel M, Cerón T, Zamudio C, Díaz-Vega A (2011) Abdominal and gastrointestinal symptoms of Dengue fever. Analysis of a cohort of 8559 patients. Gastroenterol Hepatol. 34(4):243–247
  26. ^ a b Gritsun TS, Nuttall PA, Gould EA (2003) Tick-borne flaviviruses. Adv Virus Res 61:317–371
  27. ^ Tandon BN, Acharya SK (1987) Viral diseases involving the liver. Baillieres Clin Gastroenterol 1(2):211–230
  28. ^ Xiong W (2010) Clinical efficacy of treating infant cytomegalovirus hepatitis with ganciclovir and impact on cytokines. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 26(11):11302
  29. ^ Okano M, Gross TG (2011) Acute or chronic life threatening diseases associated with Epstein Barr virus infection. Am J Med Sci.
  30. ^ GallegosOrozco JF, RakelaBrödner J (2010) Hepatitis viruses: not always what it seems to be. Rev Med Chil 138(10):13021311
  31. ^ Papic N, Pangercic A, Vargovic M, Barsic B, Vince A, Kuzman I (2011) Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. Influenza Other Respi Viruses doi: 10.1111/j.17502659.2011.00287.x.
  32. ^ Bondarenko VI, Zadorozhnaia VI (1992) The role of enteroviruses in the etiology of diseases of the pancreas, kidneys and liver. Lik Sprava (3):58–62
  33. ^ Zaidi SA, Singer C (2002) Gastrointestinal and hepatic manifestations of tickborne diseases in the United States.Clin Infect Dis 34(9):1206–1212
  34. ^ Organ EL, Rubin DH (1998) Pathogenesis of reovirus gastrointestinal and hepatobiliary disease. Curr Top Microbiol Immunol 233(2):67–83
  35. ^ Heyman P, Cochez C, Hofhuis A, van der Giessen J, Sprong H, Porter SR, Losson B, Saegerman C, Donoso-Mantke O, Niedrig M, Papa A (2010) A clear and present danger: tick-borne diseases in Europe. Expert Rev Anti Infect Ther 8(1):33–50
  36. ^ Siński E, Welc-Faleciak R, Pogłód R (2011) Babesia spp. infections transmitted through blood transfusion. Wiad Parazytol 57(2):77–81
  37. ^ Massei F, Gori L, Macchia P, Maggiore G (2005) The expanded spectrum of bartonellosis in children. Infect Dis Clin North Am 19(3):691–711
  38. ^ Yang HW, Jung SH, Han HY, Kim A, Lee YJ, Cha SW, Go H, Choi GY, Cho SH, Lim SH (2008) Clinical feature of Fitz-Hugh-Curtis syndrome: analysis of 25 cases. Korean J Hepatol 14(2):178–184
  39. ^ Figure 7.12 (Some causes of acute parenchymal damage), Parveen, M.D. Kumar (Editor), Michael, M.d. Clark (Editor) (2005). Clinical Medicine. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7020-2763-4. 
  40. ^ Blanco JR, Oteo JA (2002) Human granulocytic ehrlichiosis in Europe. Clin Microbiol Infect. 2002 Dec;8(12):763-72
  41. ^ Scholing M, Schneeberger PM, van den Dries P, Drenth JP (2007) Clinical features of liver involvement in adult patients with listeriosis. Review of the literature. Infection 35(4):212–218
  42. ^ Drebber U, Kasper HU, Ratering J, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M (2008) Hepatic granulomas: histological and molecular pathological approach to differential diagnosis—a study of 442 cases. Liver Int 28(6):828–834
  43. ^ Raby N, Forbes G, Williams R (1990) Nocardia infection in patients with liver transplants or chronic liver disease: radiologic findings. Radiology 174(3 Pt 1):713–716
  44. ^ Mohammed JP, Mattner J (2009) Autoimmune disease triggered by infection with alphaproteobacteria. Expert Rev Clin Immunol 5(4):369–379
  45. ^ Kaplan MM (2004) Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol 99(11):2147–2149
  46. ^ Selmi C, Gershwin ME (2004) Bacteria and human autoimmunity: the case of primary biliary cirrhosis. Curr Opin Rheumatol 16(4):406–410
  47. ^ Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME (2003) Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38(5):1250–1257
  48. ^ Yen TH, Chang CT, Lin JL, Jiang JR, Lee KF (2003) Scrub typhus: a frequently overlooked cause of acute renal failure. Ren Fail 25(3):397–410
  49. ^ Park JI, Han SH, Cho SC, Jo YH, Hong SM, Lee HH, Yun HR, Yang SY, Yoon JH, Yun YS, Moon JY, Cho KR, Baik SH, Son JH, Kim TW, Lee DH (2003) Outbreak of hepatitis by Orientia tsutsugamushi in the early years of the new millenium. Taehan Kan Hakhoe Chi. 9(3):198–204
  50. ^ a b Bernabeu-Wittel M, Segura-Porta F (2005) Rickettsioses. Enferm Infecc Microbiol Clin 23(3):163–172
  51. ^ Brown JM, McNeil MM (2003) Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, and other aerobic actinomycetes. p502-531. In PR Murray, EJ Baron, JH Jorgensen, MA Pfaller and RH. Yolken (ed.) Manual of clinical microbiology (8th ed.) American Society for Microbiology, Washington, D.C.
  52. ^ Connor BA, Schwartz E (2005) Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 5(10):623–628
  53. ^ Cook GC (1997) Liver involvement in systemic infection. Eur J Gastroenterol Hepatol 9(12):1239–1247
  54. ^ Bottone EJ (1997) Yersinia enterocolitica: the charisma continues. Clin Microbiol Rev. 10(2):257–276
  55. ^ a b c d e f g Seitz HM (1995) Parasitic diseases of the liver. Verh Dtsch Ges Pathol 79:241–248
  56. ^ Chen XM, LaRusso NF (2002) Cryptosporidiosis and the pathogenesis of AIDS-cholangiopathy. Semin Liver Dis 22(3):277–289
  57. ^ Michiels JF, Hofman P, Bernard E, Saint Paul MC, Boissy C, Mondain V, LeFichoux Y, Loubiere R (1994) Intestinal and extraintestinal Isospora belli infection in an AIDS patient. A second case report. Pathol Res Pract 190(11):1089–1093
  58. ^ Walther Z, Topazian MD (2009) Isospora cholangiopathy: case study with histologic characterization and molecular confirmation. Hum Pathol 40(9):1342–1346
  59. ^ Anand AC, Puri P (2005) Jaundice in malaria. J Gastroenterol Hepatol. 20(9):1322–1332
  60. ^ a b Miller TA (1979) Hookworm infection in man. Adv Parasitol 17:315–384
  61. ^ Gavin PJ, Kazacos KR, Shulman ST (2005) Baylisascariasis. Clin Microbiol Rev 18(4):703–718
  62. ^ a b Li CD, Yang HL, Wang Y (2010) Capillaria hepatica in China. World J Gastroenterol 16(6):698–702
  63. ^ Pokora Z (2001) Role of gastropods in epidemiology of human parasitic diseases. Wiad Parazytol 47(1):3–24
  64. ^ Garcia HH, Moro PL, Schantz PM (2007) Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis. Curr Opin Infect Dis 20(5):489–494
  65. ^ Mordvinov VA, Yurlova NI, Ogorodova LM, Katokhin AV (2012) Opisthorchis felineus and Metorchis bilis are the main agents of liver fluke infection of humans in Russia. Parasitol Int 61(1):25–31
  66. ^ Singcharoen T, Rawd-Aree P, Baddeley H (1988) Computed tomography findings in disseminated paragonimiasis. Br J Radiol 61(721):83–86
  67. ^ Soroczan W (1996) Strongyloidosis. II. Clinical manifestations. Wiad Parazytol 42(3):291–312
  68. ^ Fried B, Reddy A, Mayer D (2011) Helminths in human carcinogenesis. Cancer Lett 305(2): 239–249
  69. ^ Ishibashi H, Tsuchiya Y (1995) Hepatic toxocariasis. Ryoikibetsu Shokogun Shirizu (7):48–50
  70. ^ Nikeghbalian S, Salahi R, Salahi H, Bahador A, Kakaie F, Kazemi K, Malek-Hosseini SA, Janghorban P (2009) Hepatic abscesses after liver transplant: 1997–2008. Exp Clin Transplant 7(4):256–260
  71. ^ Romero FA, Razonable RR (2011) Infections in liver transplant recipients. World J Hepatol 3(4):83–92
  72. ^ Aidé MA (2009) Chapter 4—histoplasmosis. J Bras Pneumol 35(11):1145–1151
  73. ^ Chukwuma C Sr (1996) Microsporidium in AIDS patients: a perspective. East Afr Med J 73(1):72–75
  74. ^ Arcay L (2001) Human microsporidiosis. Invest Clin 42 Suppl 1:3–42
  75. ^ Atías A (1995) Update on microsporidiosis in humans. Rev Med Chil 123(6):762–772
  76. ^ Chan JC, Jeffers LJ, Gould EW, Hutson D, Martinez OV, Reddy KR, Hassan F, Schiff ER (1990) Visceral protothecosis mimicking sclerosing cholangitis in an immunocompetent host: successful antifungal therapy. Rev Infect Dis 12(5):802–807
  77. ^ Narita M, Muder RR, Cacciarelli TV, Singh N (2008) Protothecosis after liver transplantation. Liver Transpl 14(8):1211–1215
  78. ^ "Hepatitis as a result of chemicals and drugs". HealthAtoZ. Archived from the original on 2006-06-23. http://web.archive.org/web/20060623141402/http://www.healthatoz.com/healthatoz/Atoz/dc/caz/infc/hepa/hepres.jsp. Retrieved 2006-07-01. 
  79. ^ Lim JR, Faught PR, Chalasani NP, Molleston JP (2006). "Severe liver injury after initiating therapy with atomoxetine in two children". J. Pediatr. 148 (6): 831–4. doi:10.1016/j.jpeds.2006.01.035. PMID 16769398. 
  80. ^ Bastida G, Nos P, Aguas M, Beltrán B, Rubín A, Dasí F, Ponce J (2005). "Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease". Aliment Pharmacol Ther 22 (9): 775–82. doi:10.1111/j.1365-2036.2005.02636.x. PMID 16225485. 
  81. ^ Nadir A, Reddy D, Van Thiel DH (2000). "Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity". Am. J. Gastroenterol. 95 (12): 3634–7. doi:10.1111/j.1572-0241.2000.03386.x. PMID 11151906. 
  82. ^ Torbenson M, Hart J, Westerhoff M, Azzam RK, Elgendi A, Mziray-Andrew HC, Kim GE, Scheimann A (2010) Neonatal giant cell hepatitis: histological and etiological findings. Am J Surg Pathol 34(10):1498–1503
  83. ^ Krokhina NB, Ushakova RA, Kobeleva IaM (2010) Significance of hepatic biopsy specimens in the diagnosis of liver disease in babies of the first year of life. Arkh Patol 72(1):19–23
  84. ^ Hayashi H, Narita R, Hiura M, Abe S, Tabaru A, Tanimoto A, Sasaguri Y, Harada M (2011) A case of adult autoimmune hepatitis with histological features of giant cell hepatitis. Intern Med 50(4):315–319
  85. ^ Hartl J, Buettner R, Rockmann F, Farkas S, Holstege A, Vogel C, Schnitzbauer A, Schlitt HJ, Schoelmerich J, Kirchner G (2010) Giant cell hepatitis: an unusual cause of fulminant liver failure. Z Gastroenterol 48(11):1293-1266
  86. ^ Gábor L, Pál K, Zsuzsa S (1997) Giant cell hepatitis in adults. Pathol Oncol Res 3(3):215–218
  87. ^ Alexopoulou A, Deutsch M, Ageletopoulou J, Delladetsima JK, Marinos E, Kapranos N, Dourakis SP (2003) A fatal case of postinfantile giant cell hepatitis in a patient with chronic lymphocytic leukaemia. Eur J Gastroenterol Hepatol 15(5):551–555
  88. ^ Bianchi L, Terracciano LM (1994) Giant cell hepatitis in adults. Praxis (Bern 1994) 83(44):1237–1241
  89. ^ Duhaut P, Bosshard S, Ducroix JP (November 2004). "Is giant cell arteritis an infectious disease? Biological and epidemiological evidence". Presse Médicale (Paris, France : 1983) 33 (19 Pt 2): 1403–8. PMID 15615251. 
  90. ^ Shet TM, Kandalkar BM, Vora IM (1998) Neonatal hepatitis—an autopsy study of 14 cases. Indian J Pathol Microbiol 41(1):77–84
  91. ^ Hassoun Z, N'Guyen B, Cote J, Marleau D, Willems B, Roy A, Dagenais M, Lapointe R, Letourneau R, Villeneuve JP (2000) A case of giant cell hepatitis recurring after liver transplantation and treated with ribavirin. Can J Gastroenterol 14(8):729–731
  92. ^ Durand F, Degott C, Sauvanet A, Molas G, Sicot C, Marcellin P, Belghiti J, Erlinger S, Benhamou JP, Bernuau J (1997) Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. J Hepatol 26(3):722–776
  93. ^ Harmanci O, Onal IK, Ersoy O, Gürel B, Sökmensüer C, Bayraktar Y (December 2007). "Postinfantile giant cell hepatitis due to hepatitis E virus along with the presence of autoantibodies". Digestive Diseases and Sciences 52 (12): 3521–3. doi:10.1007/s10620-006-9698-8. PMID 17410455. 
  94. ^ Moreno A, Moreno A, Pérez-Elías MJ, Quereda C, Fernández-Muñoz R, Antela A, Moreno L, Bárcena R, López-San Román A, Celma ML, García-Martos M, Moreno S (October 2006). "Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature". Human Pathology 37 (10): 1344–9. doi:10.1016/j.humpath.2006.05.003. PMID 16949926. 
  95. ^ Fimmel CJ, Guo L, Compans RW, Brunt EM, Hickman S, Perrillo RR, Mason AL (1993) A case of syncytial giant cell hepatitis with features of a paramyxoviral infection. Am J Gastroenterol 93(10):1931–1937
  96. ^ Krech RH, Geenen V, Maschek H, Högemann B (1998) Adult giant cell hepatitis with fatal outcome. Clinicopathologic case report and reflections on pathogenesis. Pathologe 19(3):221–225
  97. ^ Koff RS (1991) Acute and chronic giant cell hepatitis: a paramyxovirus infection? Gastroenterology 101(3):863–864
  98. ^ Phillips MJ, Blendis LM, Poucell S, offterson J, Petric M, Roberts E, Levy GA, Superina RA, Greig PD, Cameron R, et al (1991) Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. N Engl J Med 324(7):455–460
  99. ^ Drut R, Gómez MA, Drut RM, Cueto RE, Lojo M (1998) Human papillomavirus, neonatal giant cell hepatitis and biliary duct atresia. Acta Gastroenterol Latinoam 28(1):27–31
  100. ^ Drut R, Gómez MA, Drut RM, Lojo MM (1996) Human papillomavirus (HPV)-associated neonatal giant cell hepatitis (NGCH). Pediatr Pathol Lab Med 16(3):403–412
  101. ^ Potenza L, Luppi M, Barozzi P, Rossi G, Cocchi S, Codeluppi M, Pecorari M, Masetti M, Di Benedetto F, Gennari W, Portolani M, Gerunda GE, Lazzarotto T, Landini MP, Schulz TF, Torelli G, Guaraldi G (2008) HHV-6A in syncytial giant-cell hepatitis. N Engl J Med 359(6):593–602
  102. ^ Kuntzen T, Friedrichs N, Fischer HP, Eis-Hübinger AM, Sauerbruch T, Spengler U (2005) Postinfantile giant cell hepatitis with autoimmune features following a human herpesvirus 6-induced adverse drug reaction. Eur J Gastroenterol Hepatol 17(10):1131–1134
  103. ^ Suzuki K, Nakayama H, Doi K (2001) Giant cell hepatitis in two young cats. J Vet Med Sci. 63(2):199–201

External links

Acute
Chronic
Processes
Specific locations